
0:00
7:00
A quiet week for top-tier acromegaly literature (four papers, mostly real-world/consensus rather than trial data) paired with a livelier rare disease industry week — a first-ever positive pivotal trial in X-linked retinitis pigmentosa and a new FOP approval that goes head-to-head with Regeneron — while Marea's own MAR002 acromegaly program remains the clearest bridge between the two segments following its merger with Lisata.
More episodes from "Acromegaly Update"



Don't miss an episode of “Acromegaly Update” and subscribe to it in the GetPodcast app.








